CSIMarket
 


Cellectar Biosciences Inc   (CLRB)
Other Ticker:  
 

Cellectar Biosciences Inc 's Leverage Ratio

CLRB's quarterly Leverage Ratio and Total Liabilities, Equity growth




CLRB Leverage Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity Change -66.96 % -54.09 % -45.34 % -39.69 % 137.83 %
Y / Y Total Liabilities Change 109.82 % 61.08 % -7.85 % 11.96 % -24.58 %
Leverage Ratio MRQ 0.5 0.27 0.17 0.12 0.08
Overall Ranking # # # # #
Seq. Equity Change -36.86 % -25.78 % -17.66 % -14.36 % -12.27 %
Seq. Total Liabilities Change 16.56 % 21.07 % 17.04 % 27.04 % -10.51 %



Leverage Ratio third quarter 2022 Comment
Due to net new borrowings of 16.56%, Leverage Ratio detoriated to 0.5, above company's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry Cellectar Biosciences Inc achieved lowest Leverage Ratio. While total ranking remained unchanged compare to previous quarter at no. .

Explain Leverage Ratio?
Who are CLRB Customers?
Leverage Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Leverage Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Cellectar Biosciences Inc 's Equity $ 13 Millions Visit CLRB's Balance sheet
Cellectar Biosciences Inc 's Total Liabilities $ 6 Millions Visit CLRB's Balance sheet
Source of CLRB's Sales Visit CLRB's Sales by Geography


Cumulative Cellectar Biosciences Inc 's Leverage Ratio

CLRB's Leverage Ratio for the trailling 12 Months

CLRB Leverage Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity TTM Growth -66.96 % -54.09 % -45.34 % -39.69 % 137.83 %
Y / Y Total Liabilities TTM Growth 109.82 % 61.08 % -7.85 % 11.96 % -24.58 %
Leverage Ratio TTM 0.22 0.14 0.1 0.09 0.08
Total Ranking TTM # 219 # 157 # 300 # 176 # 149
Seq. Equity TTM Growth -36.86 % -25.78 % -17.66 % -14.36 % -12.27 %
Seq. Total Liabilities TTM Growth 16.56 % 21.07 % 17.04 % 27.04 % -10.51 %


TTM Leverage Ratio Comment
On the trailing twelve months basis Due to net new borrowings of 16.56%, Leverage Ratio improved to 0.22, above Cellectar Biosciences Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 75 other companies have achieved lower Leverage Ratio than Cellectar Biosciences Inc . While total ranking remained unchanged compare to previous quarter at no. 219.

Explain Leverage Ratio?
Who are CLRB Customers?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 76
Healthcare Sector # 130
Within the Market # 219


TTM Leverage Ratio Statistics
High Average Low
0.31 0.19 0.09
(Mar 31 2020)   (Sep 30 2021)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2022 MRQ Total LiabilitiesSep 30 2022 MRQ Equity
Ani Pharmaceuticals inc  1.37 $ 427.285  Millions$ 311.825  Millions
Cumberland Pharmaceuticals Inc   1.35 $ 51.783  Millions$ 38.491  Millions
Trevena inc   1.33 $ 29.156  Millions$ 21.863  Millions
Tempest Therapeutics Inc   1.31 $ 35.024  Millions$ 26.773  Millions
Blueprint Medicines Corporation  1.28 $ 818.085  Millions$ 640.307  Millions
Prestige Consumer Healthcare Inc   1.27 $ 2,058.673  Millions$ 1,619.841  Millions
Rvl Pharmaceuticals Plc  1.26 $ 86.289  Millions$ 68.546  Millions
Pacira Biosciences inc   1.25 $ 964.242  Millions$ 770.123  Millions
Capricor Therapeutics inc   1.25 $ 19.244  Millions$ 15.426  Millions
Unicycive Therapeutics Inc   1.20 $ 5.551  Millions$ 4.626  Millions
2seventy Bio Inc   1.19 $ 385.564  Millions$ 323.180  Millions
Catalent Inc   1.17 $ 5,505.000  Millions$ 4,700.000  Millions
Ardelyx inc   1.16 $ 77.811  Millions$ 66.861  Millions
Merck and Co Inc   1.16 $ 51,546.000  Millions$ 44,524.000  Millions
Axsome Therapeutics Inc   1.15 $ 181.596  Millions$ 157.361  Millions
Mirum Pharmaceuticals Inc   1.15 $ 195.050  Millions$ 169.297  Millions
Arvinas Inc   1.15 $ 713.300  Millions$ 621.500  Millions
Marinus Pharmaceuticals Inc   1.14 $ 93.338  Millions$ 82.004  Millions
Sonoma Pharmaceuticals Inc  1.13 $ 7.941  Millions$ 7.021  Millions
Sigilon Therapeutics Inc   1.13 $ 50.208  Millions$ 44.410  Millions
Lifevantage Corp  1.12 $ 35.710  Millions$ 31.890  Millions
Geron Corp  1.11 $ 120.608  Millions$ 108.172  Millions
Royalty Pharma Plc  1.11 $ 11,520.505  Millions$ 10,416.403  Millions
Selecta Biosciences Inc  1.10 $ 93.358  Millions$ 84.907  Millions
Alaunos Therapeutics Inc   1.10 $ 35.231  Millions$ 32.113  Millions
Elanco Animal Health Inc  1.08 $ 7,287.000  Millions$ 6,745.000  Millions
Sellas Life Sciences Group Inc   1.06 $ 13.404  Millions$ 12.597  Millions
Tg Therapeutics inc   1.06 $ 106.828  Millions$ 100.481  Millions
Oncorus Inc   1.05 $ 84.369  Millions$ 79.996  Millions
Immunogen inc   1.02 $ 180.792  Millions$ 178.007  Millions

Date modified: 2022-11-06T02:10:30+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

JACK's Profile

Stock Price

JACK's Financials

Business Description

Fundamentals

Charts & Quotes

JACK's News

Suppliers

JACK's Competitors

Customers & Markets

Economic Indicators

JACK's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071